Complete and send this report within 30 days of end of study or expiration date to the WPI IRB c/o Ruth McKeogh 2nd floor Project Center. If you have any questions, please call (508) 831-6699.

WPI IRB PROTOCOL #: ___________________________ DATE OF REPORT: ___________________________
Investigator: ___________________________ Approval Expiration Date: ___________________________

Project Title: __________________________________________
Department: __________________________________________
Name: __________________________________________
Phone: __________________________________________
E-mail: __________________________________________

The Principal Investigator or designee may complete and sign this report.

The study has been:  
☐ Completed Date: ___________________________
☐ Terminated Date: ___________________________
☐ Not Begun ___________________________
☐ Inactive ___________________________

If the study is inactive, terminated or never begun, please state the reason.

1. Study Summary – (Please provide a summary for final report as soon as available.)

a. Results obtained to date, if any.  
☐ None ☐ Attached

b. Have there been any significant new findings?  
☐ Yes ☐ No

c. Has there been an interim analysis?  
☐ Yes ☐ No

d. Interim reports, findings, or abstracts are attached.  
☐ Yes ☐ No

e. Have there been any changes to the approved protocol that have not been reviewed by the WPI IRB? If yes, please explain.  
☐ Yes ☐ No

2. Subject Accrual and Follow-up:

A. Subject Goal (Total number of subjects anticipated at onset of study.)

B. Actual Subjects

• Total number of subjects who signed consent form at your site:
• Number of screen failures (signed consent form and did not enroll):
• Number of subjects who were discontinued due to an adverse event:
• Number of subjects who withdrew, were lost to follow-up or were discontinued (not due to an adverse event):

Please summarize why subjects dropped out or were discontinued at your site:

• Number of subjects who completed the study:

C. If there is a discrepancy in actual versus anticipated subject numbers, please explain why this might have occurred:
D. Subject Categories (this section is **mandatory** for studies with Federal funding and **optional** for other studies)

1. Specific target:

2. If your population is general, please submit the following:

Please provide the percentage of subjects accrued in each of the following categories:

<table>
<thead>
<tr>
<th>American Indian/Alaskan Native</th>
<th>Asian/Pacific Islander</th>
<th>Hispanic</th>
</tr>
</thead>
<tbody>
<tr>
<td>White, Not Hispanic</td>
<td>Black, Not Hispanic</td>
<td>Other or unknown</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Percent of subjects that are female</th>
<th>Percent of subjects that are male</th>
<th>Percent of subjects that are minors</th>
</tr>
</thead>
</table>

Is your subject data similar to the demographics of your geographic location?  

- [ ] Yes  
- [ ] No

You may obtain local demographic data at the website: [http://www.census.gov/](http://www.census.gov/). You may search for your city or county. If you use another source to obtain demographics, please list here:

**Whether you use census data or another source for local demographics, please attach a copy.**  

- [ ] Attached

If your accrual data is not comparable to the demographics of your location, provide an explanation as to why your subject demographics do not match the demographics of your area. For example, the condition being studied may be more prevalent in a certain population.

3. **Serious Adverse Events** (A serious adverse event can be any serious undesired and unintended, although not necessarily unexpected, effect of the research occurring in subjects as a result of the interventions or interactions used in the research, or from the collection of privately identifiable research data)

   Number of Serious Adverse Events which occurred at your site:

   - [ ] Yes  
   - [ ] No  
   - [ ] N/A

   Include reports of all **serious** Adverse Events not previously reported.

   In addition, if the WPI IRB is not the central IRB for this study, please submit all sponsor generated reports.

4. **Informed Consent**

   a) Have all subjects signed and received a copy of the approved informed consent document?  
      - [ ] Yes  
      - [ ] No

      If no, please explain:

   b) Please include a copy of the informed consent for the last subject consented at your site.  
      - [ ] Attached

      *(Please black out the subject’s name only – do NOT black out the date the subject signed)*
5. **Study Data** – Studies cannot be closed if identifiable data from the study still exists, because the release of identifiable data may cause harm to study subjects. Check all of the following as they apply to your study:

- All data collected from human subjects as a part of this study has been destroyed and is no longer accessible by the investigators or others.
- All personally identifiable information collected from human subjects as a part of this study has been removed from the study records and data bases.
- All “keys” or records that link study subjects with their data have been destroyed and no mechanism exists for re-identifying subject data.
- I intend to make de-identified study data publicly available for other researchers to use.

_________________________________________  Date:  __________________________

Signature

_________________________________________

Printed Name